BioMarin Pharmaceuticals Inc (BMRN): Today's Featured Health Care Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

BioMarin Pharmaceuticals ( BMRN) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 0.3%. By the end of trading, BioMarin Pharmaceuticals fell 60 cents (-1.2%) to $48.09 on light volume. Throughout the day, 811,986 shares of BioMarin Pharmaceuticals exchanged hands as compared to its average daily volume of 1.7 million shares. The stock ranged in price between $47.60-$48.66 after having opened the day at $48.58 as compared to the previous trading day's close of $48.69. Other companies within the Health Care sector that declined today were: Geron Corporation ( GERN), down 23%, Neuralstem ( CUR), down 19.5%, CEL-SCI Corporation ( CVM), down 18%, and Electromed ( ELMD), down 14.3%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world. BioMarin Pharmaceuticals has a market cap of $6.01 billion and is part of the drugs industry. Shares are up 41.6% year to date as of the close of trading on Monday. Currently there are 11 analysts that rate BioMarin Pharmaceuticals a buy, no analysts rate it a sell, and five rate it a hold.

TheStreet Ratings rates BioMarin Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and feeble growth in the company's earnings per share.

On the positive front, Biostar Pharmaceuticals ( BSPM), up 20.4%, Medgenics ( MDGN), up 12.5%, Cynosure ( CYNO), up 10.7%, and Galena Biopharma ( GALE), up 9.8%, were all gainers within the health care sector with Perrigo Company ( PRGO) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.

If you liked this article you might like

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Trump's FDA: A Friendlier Biotech Sheriff

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half

3 Fearless Predictions for the Second Half